Bank of Nova Scotia Boosts Regeneron Pharmaceuticals Holdings

Institutional investor increases stake in biotech firm by 11.7% in Q3

Mar. 15, 2026 at 9:22am

Got story updates? Submit your updates here. ›

Bank of Nova Scotia, a major Canadian financial institution, increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.7% during the third quarter of 2025, according to a recent SEC filing. The fund now owns 278,551 shares of the biopharmaceutical company's stock, worth approximately $156.6 million.

Why it matters

Regeneron is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. The increased investment by a major institutional investor like Bank of Nova Scotia signals confidence in the company's long-term growth prospects.

The details

In its 13F filing, Bank of Nova Scotia reported purchasing an additional 29,273 shares of Regeneron during the third quarter, bringing its total stake to 278,551 shares. This represents about 0.27% ownership in the $78.8 billion company.

  • Bank of Nova Scotia increased its Regeneron holdings in Q3 2025.

The players

Bank of Nova Scotia

A major Canadian financial institution and one of the largest banks in North America.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Bank of Nova Scotia in Regeneron Pharmaceuticals reflects the bank's confidence in the biotech firm's long-term growth potential and innovative drug pipeline. This is a positive signal for Regeneron as it continues to advance its therapies through clinical development and commercialization.